The STOP-PKD Study
The STOP-PKD study is a new multicentre study involving several European countries and universities, investigating a potential new treatment option for people living with autosomal dominant polycystic kidney disease (ADPKD). The study focuses on dapagliflozin, a medicine from the SGLT2 inhibitor class that is already approved and widely used for several other kidney diseases. Until now, however, people with ADPKD have been excluded from clinical trials with this type of medication.
This important study, led by the University of Cologne, aims to address this gap by exploring whether dapagliflozin could also help slow disease progression or provide clinical benefits for people with ADPKD.